Source: Eur Respir J 2007; 30: 1038-1040



Rating:

Share or cite this content

Citations should be made in the following way:
Kawut S. M.. Caring for the orphan's orphan: treatment of patients with portopulmonary hypertension. Eur Respir J 2007; 30: 1038-1040

Member's Comments

No comment yet.

Related content which might interest you: Rare pulmonary disease and orphan drugs: a path to the future Source: Eur Respir Rev, 28 (153) 190115; 10.1183/16000617.0115-2019 Year: 2019 Treatment of lymphangioleiomyomatosis: building evidence in orphan diseases Source: Eur Respir J 2014; 43: 966-969 Year: 2014 How should we treat portopulmonary hypertension? Source: Eur Respir J 2006; 28: 466-467 Year: 2006 Bronchiectasis: how to be an orphan with many parents? Source: Eur Respir J 2016; 47: 10-13 Year: 2016 Toward better management of rare and orphan pulmonary diseases Source: Eur Respir J 2016; 47:1334-1335 Year: 2016 Chronic post-embolic pulmonary hypertension: a new target for medical therapies?}, Source: Eur Respir Rev 2013; 22: 258-264 Year: 2013 Survival in portopulmonary hypertension (PoPH) in the era of modern PAH-targeted therapy Source: International Congress 2018 – Clinical aspects of pulmonary hypertension Year: 2018 Rare pulmonary diseases and orphan drugs: where do we stand and where are we going to? Source: Eur Respir Rev 2015; 24: 375-377 Year: 2015 Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension Source: Eur Respir J 2013; 41: 96-103 Year: 2013 Ambrisentan for therapy of portopulmonary hypertension (POPH): Update on safety and efficacy Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012 Bosentan therapy for portopulmonary hypertension Source: Eur Respir J 2005; 25: 502-508 Year: 2005 Optimising pharmacotherapy in patients with pulmonary arterial hypertension and comorbidities, including lung diseases and heart failure: benefits without harm? Source: International Congress 2018 – Integrated care for patients with pulmonary vascular disease, lung diseases and heart failure Year: 2018 Interventional treatment of pulmonary hypertension: where are we now? Source: Virtual Congress 2020 – Breathing disorders and cardiovascular diseases Year: 2020 Managing chronic thromboembolic pulmonary hypertension: pharmacological treatment options Source: Eur Respir Rev 2009; 18: 24-28 Year: 2009 Physicians’ and patients’ expectations of therapies for pulmonary arterial hypertension: where do they meet? Source: Eur Respir Rev 2014; 23: 458-468 Year: 2014 Treatment of pulmonary hypertension due to COPD: can we really hope in better? Source: Eur Respir J 2005; 26: Suppl. 49, 562s Year: 2005 Chronic thromboembolic pulmonary hypertension: do we need a new definition? Source: Eur Respir J 2014; 44: 1401-1403 Year: 2014 Safety and efficacy of immunoadsorption as an add-on to medical treatment in patients with idiopathic pulmonary arterial hypertension Source: International Congress 2017 – Outcomes and new treatment strategies in pulmonary hypertension Year: 2017